PeptiStrong,
does it really help with Increased strength and muscular endurance when combined with resistance training?
research showsPeptiStrong is rated C because a strength and endurance signal exists, but the primary 1RM analysis in the 72-person eight-week trial was null. Between-group differences in change from baseline had p=.096 at day 28 and p=.125 at day 56. Positive findings came only from one-tailed tests and between-group comparisons at individual time points. A 30-person recovery trial was also small, and both studies were Nuritas-led, yielding C with 41 points.
ads claimMarketing can expand AI-discovered peptides and mTOR or myostatin changes into guaranteed muscle gain and superiority over ordinary protein. Direct evidence is limited to an eight-week training trial and a short muscle-damage recovery trial in healthy younger adults; long-term hypertrophy, older-adult function, and superiority to standard protein remain unestablished.
Useful facts when choosing a product
- PeptiStrong is a Nuritas-branded hydrolysate of fava-bean protein, and both published human trials used 2.4 g daily. Labels should be checked for the branded-ingredient amount and other proteins or additives.
- Efficacy participants were healthy adults aged 19 to 45, and one trial paired supplementation with structured resistance training. There is no direct evidence of the same result in older adults, sarcopenia, or rehabilitation patients.
- No prominent safety signal appeared in the short trials and tolerability was generally favorable, but long-term and large-population safety evidence is limited. People allergic to fava beans or other legumes should avoid it.
- Because fava-derived foods are associated with favism in glucose-6-phosphate dehydrogenase deficiency, people with G6PD deficiency should verify manufacturing specifications, residual constituents, and suitability with a clinician.
What the research actually shows
The 2025 trial gave untrained adults identical eight-week resistance training plus Vicia faba hydrolysate 2.4 g/day or placebo. Between-group change-from-baseline 1RM was null at day 28 with p=.096 and day 56 with p=.125; positive findings were limited to one-tailed comparisons between groups at individual time points. The 2023 trial assessed recovery in 30 men and found positive integrated measures but no strength difference at individual time points. Nuritas participated throughout both studies.
Why this is classified as C (41)
In the 72-person eight-week trial, change-from-baseline 1RM was null at day 28 with p=.096 and day 56 with p=.125, while positive results relied on one-tailed, time-specific comparisons. The 30-person recovery signal was limited to integrated analyses, and all evidence was Nuritas-led. Limited supportive signals give C with 41 points.
Counterpoint. Progressive resistance training, adequate total protein and energy, and recovery remain central. There is no evidence that PeptiStrong is superior to ordinary dietary protein or produces the same effect without exercise.
Rejudgment record. New verdict — Reflected null change-from-baseline 1RM results at day 28 with p=.096 and day 56 with p=.125, positive findings limited to one-tailed time-specific comparisons, integrated signals in a 30-person recovery study, and full Nuritas involvement
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Increased strength and muscular endurance with resistance training | C | A 72-person short trial was positive, but borderline analyses and full developer involvement limit confidence. |
| Independent replication separate from the developer | ? | Every identified human efficacy trial involved Nuritas in funding, design, analysis, and publication. |
| Superiority to ordinary dietary protein or other protein supplements | ? | No human trial with an isonitrogenous protein comparator and long-term hypertrophy has established superiority. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Mohan NM et al. 2025 | Eight-week randomized double-blind placebo-controlled resistance-training trial | 66 | Fully supported by Nuritas; all authors were employees and the company controlled design, analysis, and publication | Bilateral leg-extension 1RM primary outcome; repetitions to exhaustion, body composition, and markers | Day-28 and day-56 1RM and change in repetitions favored the supplement, but day-56 p=.05 and some tests were one-tailed. | Pivotal direct positive but borderline manufacturer trial |
| Kerr A et al. 2023 | Randomized double-blind placebo-controlled exercise-induced muscle-damage trial | 30 | Funded by Nuritas; the company and study site controlled design, collection, analysis, and publication | 48- and 72-hour peak-torque/body-weight recovery, fatigue index, and myokines | Integrated 72-hour recovery and fatigue were positive, but strength did not differ significantly at individual time points. | Small short-term supportive evidence |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-20).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-20 · Corrections: none
Cite this verdict
[Chamgap] PeptiStrong x increased strength and muscular endurance with resistance training — Evidence Grade C·41. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/sports/peptistrong-vicia-faba-hydrolysate-strength-endurance-resistance-training/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.